FDA label
What is Nourianz used for?
Nourianz contains istradefylline. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.
Source: DailyMed SPL label file dated 2026-10-23. Publisher page
The FDA label says: “NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes.”
Run it in Rivvi
Which 2027 plans near you dropped or restricted Nourianz?
Tier changes and new prior auth, step therapy or quantity limits, plan by plan.
Free to start. Opens Rivvi, the AI workspace for healthcare teams.
Nourianz, tablet, film coated
Indications and Usage, quoted from the label by Kyowa Kirin, Inc. (NDA022075). Cross-references to other label sections are left out.
NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes.
Source: DailyMed label, set id a7d008cb-b273-4049-a5d2-9c6902910d58, version 6, effective May 20, 2025. NDC 42747-602, one of 2 listings for this product.
Questions
What is Nourianz used for?
The FDA label says: “NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes.”
Does this page cover off-label uses or dosing?
No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.